Anita Nelson, MD, discusses the FDA's approval extending etonogestrel implant use to 5 years and the new REMS certification clinicians must complete by February 23, 2027.
|Videos|February 4, 2022
Michal Elovitz, MD, discusses new preterm birth data at SMFM
Author(s)Morgan Ebert
In this exclusive video interview, Michal Elovitz, MD, chief medical advisor at Mirvie, discusses the latest data from the RNA testing platform in predicting preterm birth at the SMFM 42nd Annual Pregnancy Meeting.
Advertisement
Michal Elovitz, MD is the Hilarie L. Morgan and Mitchell L. Morgan President’s Distinguished Professor in Women’s Health at the Perelman School of Medicine at the University of Pennsylvania and Chief Medical Advisor at Mirvie.
Advertisement
Related to this article
Get caught up with Contemporary OB/GYN! This list helps you navigate our top stories from the week, all in one place.
The FDA office of Women's Health and Center for Drug Evaluation and Research and hosting a public workshop with a focus on testosterone use in menopausal women.
FDA accepted for review an sNDA for MIUDELLA copper IUD for a 6-year duration, with a PDUFA date in Q2 2027.
Get caught up with Contemporary OB/GYN! This list helps you navigate our top stories from the week, all in one place.
Atogepant reduced perimenstrual migraine days vs. placebo and met all 8 secondary endpoints in the Phase 3 LUNA study.
Get caught up with Contemporary OB/GYN! This list helps you navigate our top stories from the week, all in one place.
Placentas from older mothers held less NAD+, and in aged pregnant mice, nicotinamide riboside or the CD38 inhibitor 78c restored placental NAD+ and improved fetal growth.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
Contemporary OB/GYN launches 'Missed & Dismissed' podcast to explore diagnostic gaps in women's health
2
Menopause proteomic scores associated with cognitive aging, dementia risk
3
Q&A: Anita Nelson, MD, on etonogestrel implant's 5-year approval and REMS certification
4
FDA approves IDE for pivotal study of Evident ovarian cancer screening test
5